WeHand-Bio key facts
as of Oct 2026- Developer and manufacturer of first-in-class natural drug innovations and advanced drug delivery systems designed for the treatment of complex metabolic disorders, malignant tumors, and…
- WeHand-Bio is valued at approximately $566.6M as of Oct 2026 (last reported valuation).
- It has raised $162.0M; the latest was IPO in Feb 2026.
- Notable investors include Cowin Capital, Shun Xi Fund, Lapam Capital, Zero2IPO Venture Capital, Beishang Capital Management (Beijing) — 10 tracked in total.
- Status: In IPO Registration.
WeHand-Bio's last reported valuation, Sep 2025. Nothing priced has surfaced since.
- ·Watch WeHand-Bio: the Monday email on marks, rounds and moves
WeHand-Bio funding rounds
No funding rounds for WeHand-Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
WeHand-Bio valuation
WeHand-Bio's last reported valuation was $567 million in Sep 2025. No priced round, secondary trade or fund mark has surfaced since.
WeHand-Bio investors
10 investors are on record for WeHand-Bio, including Cowin Capital, Shun Xi Fund, Lapam Capital and Zero2IPO Venture Capital.
About WeHand-Bio
Developer and manufacturer of first-in-class natural drug innovations and advanced drug delivery systems designed for the treatment of complex metabolic disorders, malignant tumors, and inflammatory-immune diseases. The company provides multi-component synergistic therapies and precision targeted release platforms, enabling patients and clinicians with enhanced safety, efficacy, and systemic regulatory solutions for difficult-to-treat conditions.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2010
- Employees
- 535
- Website
- wehandbio.com/
- Ownership
- In IPO Registration
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.